One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study. (2nd July 2020)

• Record Type: Journal Article
• Authors: Chimenti, Maria Sole; Fonti, Giulia Lavinia; Conigliaro, Paola; Sunzini, Flavia; Scrivo, Rossana; Navarini, Luca; Triggianese, Paola; Peluso, Giusy; Scolieri, Palma; Caccavale, Rosalba; Picchianti Diamanti, Andrea; De Martino, Erica; Salemi, Simonetta; Birra, Domenico; Altobelli, Alessio; Paroli, Marino; Bruzzese, Vincenzo; Laganà, Bruno; Gremese, Elisa; Conti, Fabrizio; Afeltra, Antonella; Perricone, Roberto
• Is Part Of: Expert opinion on biological therapy. Volume 20:Number 7(2020)
• Page Start: 813
• Page End: 821
• Publication Date: 2020-07-02
• Subjects: Ankylosing spondylitis -- psoriatic arthritis -- secukinumab -- real-life -- retention rate; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2020.1761957
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Background: Secukinumab (SEC) is effective for ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in randomized trials, but real-life data are lacking. Research design and methods: Real-life, prospective observational study on 169 consecutive outpatients at baseline (T0) and at 6 (T6) and 12 months (T12) after starting SEC (39 AS, 23%; 130 PsA, 77%). Results: Significant improvement was seen at T6 and T12 for all clinical variables, including TJC, SJC, ESR, CRP, DAPSA, ASDAS-CRP, and BASDAI, as well as in patient-reported outcomes like VAS-pain. By multivariable regression analysis, in AS patients high BASDAI at T0 correlated with diagnostic delay (R 2 = 0.4; p = 0.009) and peripheral joint involvement (R 2 = 0.4; p = 0.04). During follow-up, reduction of BASDAI positively correlated with high ESR (R 2 = 0.65; p = 0.04). ASDAS-CRP at T0 positively correlated with high ESR (R 2 = 0.34; p = 0.004). Reduction of ASDAS-CRP from T0 to T6 correlated with current smoking status (R 2 = 0.42; p = 0.003). In PsA patients, reduction of DAPSA score from T0 to T12 is negatively correlated with the presence of metabolic syndrome (R 2 = 0.41; p = 0.0025). SEC was well tolerated; 10 patients discontinued treatment for non-severe adverse events. Conclusions: Secukinumab is effective and safe in patients with AS and PsA in a real-life setting.